Grafting is a widely used agricultural technique, but the slow and unreliable healing of graft unions often limits its efficiency.

Immortal Dragons, a Singapore-based longevity fund, has announced its further support for 3D biofabrication as a primary ...

Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...

According to MarketsandMarkets™, the peripheral vascular devices market is projected to grow from about USD 10.02 billion in 2026 to USD 13.22 billion by 2031, at a CAGR of 5.7%.

MemorialCare Orange Coast Medical Center is the only hospital in Orange County to earn six consecutive three-star ratings from The Society of Thoracic Surgeons for coronary artery bypass grafting ...

Humacyte’s Symvess® is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA).

According to MarketsandMarkets, the peripheral vascular devices market is projected to grow from about USD 10.02 billion in 2026 to USD 13.22 ...

The recently passed federal defense budget for 2026 includes dedicated funding for the use of bioengineered blood vessels ...

The Health First cardiothoracic surgery program was prominently featured this month at the Society of Thoracic Surgeons conference.

As debate over equity in medicine continues nationwide, one Brooklyn hospital offers a clear picture of what progress looks like: at Maimonides Medical Center in Borough Park, women surgeons are ...

Humacyte (HUMA) stock jumps as Congress backs DoD funding to buy bioengineered vessels such as the company's lead product, Symvess. Read more here.